OCT 16 2026
Aicuris Anti-infective Cures AG — pritelivir
for acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised adults
About
Pritelivir is an antiviral drug that blocks the action of a key protein the herpes simplex virus needs to copy itself and spread. For immunocompromised individuals, who are vulnerable to infections that resist standard treatments, this direct mechanism could provide a needed alternative when other therapies fail.
Pivotal trial
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once w...
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on pritelivir
- Oral Pritelivir Outperforms Investigator’s Choice in Refractory HSV in Immunocompromised Patients - Infectious Disease Special Edition
- ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients - Pharmaceutical Technology
- Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026 - GlobeNewswire
- Pritelivir Shows Superior Efficacy for HSV in Immunocompromised Patients in phase 3 trial - Medical Dialogues
- [CROI 2026] [Press release] Aicuris: Pritelivir demonstrates superior efficacy in people living with HIV with refractory HSV in Phase 3 PRIOH-1 - European AIDS Treatment Group